ChIP Assay Plate for High Throughput Epigenomics
![](/46/pdcnewsitem/03/27/34/wEyFyAF43nXM2aW.jpg)
Porvair Sciences has announced that it will officially launch Chromatrap 96 HT — an innovative 96-well chromatin immunoprecipitation (ChIP) assay plate at Epigenomics of Common Diseases (Wellcome Trust, Cambridge, UK) from 7–10 November 2013.
The Chromatrap 96 HT is a new high throughput ChIP microplate based on the novel spin-column ChIP technology. It is essentially 96 separate Chromatrap spin-columns in one device designed to enable researchers to perform up to 96 ChIP experiments in parallel. Assays can be performed either by using hand-held multichannel pipette or by using automated liquid handling robots for even higher throughputs.
The volume and dimensions of the wells in the microplate are very similar to that of the established Chromatrap Spin-columns so the optimised spin-column protocol forms the basis of the approach to performing high throughput ChIP analysis in microplates. Each well has its own porous disc at the bottom in which protein A or protein G has been covalently attached. The functionalised discs have the same chemistry and stoichiometry as the spin columns so all of the reagent volumes and timings can be directly inferred from the spin-tube protocol. The microplate is supplied with a close fitting collection plate to recover the retained chromatins at the elution step.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance